Literature DB >> 32234453

Follow-up of asymptomatic patients with SARS-CoV-2 infection.

X Zhou1, Y Li1, T Li2, W Zhang3.   

Abstract

Entities:  

Keywords:  Asymptomatic; COVID-19; SARS-CoV-2; chronic carrier; subclinical infection

Mesh:

Year:  2020        PMID: 32234453      PMCID: PMC7271011          DOI: 10.1016/j.cmi.2020.03.024

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


× No keyword cloud information.
To the editor, Asymptomatic people with SARS-CoV-2 infection are of great concern as they undermine control interventions that rely on identifying symptomatic cases. However, current reports of asymptomatic infections were mostly cross-sectional case reports [[1], [2], [3], [4], [5]]. Do they develop symptoms later? Is an asymptomatic period a part of the natural course of coronavirus disease 2019 (COVID-19), or a chronic condition? Is the asymptomatic patient in an incubation period or a subclinical infection, or are they a chronic asymptomatic carrier of SARS-CoV-2 like Typhoid Mary? These questions are of great significance for understanding the spectrum, natural history and epidemiology of COVID-19. Therefore, we followed up virologically confirmed COVID-19 patients in Shanghai Public Health Centre who had no subjective symptoms on admission. As of March 4th, 2020, a total of 328 adults were diagnosed with COVID-19 in Shanghai. Among them, 13 patients were asymptomatic at the diagnosis (Fig. 1 ). They also had no subjective symptoms within 2 weeks before admission. Their oral temperature was no more than 37.3°C on admission. All of them were close contacts of the confirmed cases and were admitted to Shanghai Public Health Clinic Centre within 48 h after diagnosis was established. Their mean age was 51.8 years (range: 25–80 years). Six of them were male. On admission, patients revealed slight laboratory abnormalities. Leucocytes were below the normal range in two patients (15.4%). Ten patients (76.9%) had differing degrees of elevation of the erythrocyte sedimentation rate. Liver function, renal function, and coagulation function were within the normal range, as were the levels of lactate dehydrogenase and procalcitonin.
Fig. 1

Chronology of symptoms, radiographic findings, and identification of positive SARS-CoV-2 findings on qRT-PCR among asymptomatic patients in Shanghai. The numbers on the top indicate the number of days since admission. qRT-PCR, quantitative RT-PCR.

Chronology of symptoms, radiographic findings, and identification of positive SARS-CoV-2 findings on qRT-PCR among asymptomatic patients in Shanghai. The numbers on the top indicate the number of days since admission. qRT-PCR, quantitative RT-PCR. During follow-up, three patients developed symptoms at the second day of hospitalization, including sore throat, non-productive cough, chest distress, and diarrhoea (patients 1–3). The other ten patients remained asymptomatic. All patients underwent chest CT scan at admission and were followed up every 3 days. Twelve of them showed multiple ground-glass opacities that characterized SARS-CoV-2 pneumonia on admission (patients 1–3, 5–13), and four of these showed radiographic progression during hospitalization, but all showed improvement before discharge (patients 1–3 and 12). Patient 4 remained asymptomatic and had no evidence of radiographic abnormalities consistent with COVID-19. All patients tested SARS-CoV-2-RT-PCR-negative at a median time of 13 days (range 3–19 days). When we find an RT-PCR-positive patient with no subjective symptoms, there are several possibilities. First, the patient is in the incubation period. The incubation period occurs in an acute disease, and is the time between the moment of exposure to an infectious agent and the appearance of signs and symptoms of the disease. In other words, this patient will develop symptoms or signs later, but has not yet done so. Second, the patient has developed signs, such as pneumonia on chest CT, but has not yet had subjective symptoms. This patient is actually in the period of illness. This is the case for our patients 5–13, and also for patients 1–3 before their symptom onset. Third, if this patient turns RT-PCR-negative later and has never experienced symptoms or signs, this patient should be regarded as having a subclinical infection, like patient 4 in our cohort. Fourth, if this patient continues to be asymptomatic and has no signs, and the RT-PCR remains positive for a long time, then this patient is an asymptomatic chronic carrier. No such cases were found in our cohort as all patients turned RT-PCR-negative in 3 weeks. These four types of asymptomatic patients have completely different significance for the disease spectrum and natural history of COVID-19. If we can make a diagnosis early enough, we should be able to detect patients in the incubation period. In our cohort, three patients (patients 1–3) developed symptoms later and became typical COVID-19 patients. We also found that 2.7% of patients (9/328) continued asymptomatic even with pulmonary involvement (patients 5–13). Although they underwent the pathological process of pneumonia, like most COVID-19 patients, they were blind spots for control interventions based on symptomatic case screening because they never developed symptoms. We did not find chronic asymptomatic carriers in our cohort. There have been no previous cases of human chronic carriers of coronaviruses, including SARS-CoV and MERS-CoV. We think that there is probably no chronic carrier state for SARS-CoV-2. Although subclinical infections accounted for only 0.3% of our cohort (1/328, patient 4), it represents only the tip of the iceberg. The proportion of subclinical infections should be derived from future serological studies. A positive nasopharyngeal-swab or throat-swab RT-PCR for SARS-CoV-2 in an asymptomatic patient suggests that they may have the potential to infect others. However, the viral loads and infectivity of these patients may vary widely. Due to limited resources, we did not perform these tests. Further investigations are needed to determine the potential for and mode of contagion of asymptomatic patients to develop more scientific control strategies.

Author contributions

XZ and YL contributed equally to this work. Conception or design of the work: XZ, YL, WZ. Data collection and patient care: TL, WZ. Data analysis and drafting the article: XZ, YL. Critical revision of the article: WZ. Final approval of the version for publication: all of the authors.

Transparency declaration

The authors declare no competing interests. No funding was received for this work.
  5 in total

1.  Presumed Asymptomatic Carrier Transmission of COVID-19.

Authors:  Yan Bai; Lingsheng Yao; Tao Wei; Fei Tian; Dong-Yan Jin; Lijuan Chen; Meiyun Wang
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

2.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.

Authors:  Camilla Rothe; Mirjam Schunk; Peter Sothmann; Gisela Bretzel; Guenter Froeschl; Claudia Wallrauch; Thorbjörn Zimmer; Verena Thiel; Christian Janke; Wolfgang Guggemos; Michael Seilmaier; Christian Drosten; Patrick Vollmar; Katrin Zwirglmaier; Sabine Zange; Roman Wölfel; Michael Hoelscher
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

3.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

4.  Asymptomatic cases in a family cluster with SARS-CoV-2 infection.

Authors:  Xingfei Pan; Dexiong Chen; Yong Xia; Xinwei Wu; Tangsheng Li; Xueting Ou; Liyang Zhou; Jing Liu
Journal:  Lancet Infect Dis       Date:  2020-02-19       Impact factor: 25.071

5.  A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China.

Authors:  Rui Huang; Juan Xia; Yuxin Chen; Chun Shan; Chao Wu
Journal:  Lancet Infect Dis       Date:  2020-02-28       Impact factor: 25.071

  5 in total
  45 in total

1.  Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan.

Authors:  Xiaojuan Peng; Qi Liu; Zhaolin Chen; Guiyan Wen; Qing Li; Yanfang Chen; Jie Xiong; Xinzhou Meng; Yuanjin Ding; Ying Shi; Shaohui Tang
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

2.  Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.

Authors:  Wen-Pin Tseng; Jhong-Lin Wu; Chen-Chi Wu; Kuan-Ting Kuo; Chien-Hao Lin; Ming-Yi Chung; Ya-Fan Lee; Bey-Jing Yang; Chien-Hua Huang; Shey-Ying Chen; Chong-Jen Yu; Shyr-Chyr Chen; Po-Ren Hsueh
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

3.  Clinical Characteristics and Risk Factors for Severe Outcomes of Novel Coronavirus Infection, January-March 2020, Japan.

Authors:  Yuuki Tsuchihashi; Yuzo Arima; Takuri Takahashi; Kazuhiko Kanou; Yusuke Kobayashi; Tomimasa Sunagawa; Motoi Suzuki
Journal:  J Epidemiol       Date:  2021-06-22       Impact factor: 3.211

Review 4.  Monitoring approaches for health-care workers during the COVID-19 pandemic.

Authors:  Julia A Bielicki; Xavier Duval; Nina Gobat; Herman Goossens; Marion Koopmans; Evelina Tacconelli; Sylvie van der Werf
Journal:  Lancet Infect Dis       Date:  2020-07-23       Impact factor: 25.071

Review 5.  The Role of Antibody Testing for SARS-CoV-2: Is There One?

Authors:  Elitza S Theel; Patricia Slev; Sarah Wheeler; Marc Roger Couturier; Susan J Wong; Kamran Kadkhoda
Journal:  J Clin Microbiol       Date:  2020-07-23       Impact factor: 5.948

6.  SARS-CoV-2 Shedding from Asymptomatic Patients: Contribution of Potential Extrapulmonary Tissue Reservoirs.

Authors:  Raj Kalkeri; Scott Goebel; Guru Dutt Sharma
Journal:  Am J Trop Med Hyg       Date:  2020-05-13       Impact factor: 2.345

7.  Early implementation of protective measures defines surgical outcomes in the COVID-19 pandemic.

Authors:  Ana Senent-Boza; Inmaculada Benítez-Linero; Luis Tallón-Aguilar; Alejandro Sánchez-Arteaga; Lidia Melero-Cortés; Felipe Pareja-Ciuró; Javier Padillo-Ruiz
Journal:  Surg Today       Date:  2020-07-22       Impact factor: 2.549

Review 8.  Population (Antibody) Testing for COVID-19-Technical Challenges, Application and Relevance, an English Perspective.

Authors:  Peter A C Maple
Journal:  Vaccines (Basel)       Date:  2021-05-24

9.  Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in Korea.

Authors:  Pyoeng Gyun Choe; Eun Kyo Kang; Sun Young Lee; Boram Oh; Dahae Im; Hyo Yeon Lee; Hyemin Jung; Chang Kyung Kang; Min Sun Kim; Wan Beom Park; Eun Hwa Choi; BeLong Cho; Myoung-Don Oh; Nam Joong Kim
Journal:  Korean J Intern Med       Date:  2020-05-29       Impact factor: 2.884

Review 10.  Potential for elimination of SAR-CoV-2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination.

Authors:  Ji-Ming Chen; Ying-Xue Sun; Ji-Wang Chen
Journal:  J Med Virol       Date:  2020-06-29       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.